Electra Therapeutics Inc. (ETRA)
ETRA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ETRA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2026 |
| SEC CIK | 0002088082 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
New registrant: no annual report filed under this company yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $256.4M cash. | Report 2026-09-30 |
| Shares outstanding | 62,866,792 (2026-11-06). | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Mateo, California, United States | PCAOB Form AP 2026-09-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $20.0M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$23.9M | Not filed | $256.4M | $0 | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2026-06-30 | Not filed | -$26.7M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2026-03-31 | Not filed | -$22.2M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2025-09-30 | Not filed | -$18.1M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2025-06-30 | Not filed | -$17.6M | Not filed | Not filed | $40.0M | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2025-03-31 | Not filed | -$7.8M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2026-09-18 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 41 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +13.3% |
| 1 month | +2.7% |
| 3 months | Not enough price history |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -36.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ENTX | Entera Bio Ltd. | $3.02 | -2.89% | $525.9M |
| VALN | Valneva SE | $5.65 | -0.18% | $536.1M |
| DNA | Ginkgo Bioworks Holdings Inc. | $8.50 | -11.55% | $551.0M |
| IAM | Iambic Therapeutics Inc. | $11.85 | -9.54% | $561.7M |
| SANA | Sana Biotechnology Inc. | $1.88 | -6.93% | $563.3M |
| RGNX | REGENXBIO Inc. | $7.32 | -4.19% | $484.0M |
| CADL | Candel Therapeutics Inc. | $5.81 | -6.29% | $455.8M |
| FENC | Fennec Pharmaceuticals Inc. | $12.76 | +9.81% | $450.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier